ストックスクリーナーアプリを入手
4.98
5.32%
0.28
Passage Bio Inc (PASG) 最新ニュース
Lynx1 Capital Management LP Increases Stake in Passage Bio Inc - GuruFocus
Passage Bio explores gene therapy potential as investors weigh long-term prospects - AD HOC NEWS
Lynx1 Capital Management Discloses Investment at Passage BIO with 21.0% Stake - TradingView
Passage Bio (PASG) Slides 6% as Shares Test Key Support Near $4.35AD Line Divergence - dars.gov.et
PASGPassage Bio Inc Latest SEC Filings - Finviz
Latham & Watkins Advises Remix Therapeutics in Merger With Passage Bio - Legal Desire Media and Insights
Passage Bio (PASG) holder adds 50,055 shares in open-market buy - Stock Titan
Passage Bio to Merge With Remix in Deal Backed by $100 Million Financing - MyChesCo
Passage Bio, Inc. Actuals & Estimates (NASDAQ:PASG) - TradingView
Enterprise value to EBIT forward of Passage Bio, Inc. – NASDAQ:PASG - TradingView
Layoff Tracker: Biogen axes ‘small number’ of Apellis roles after $5.6B buy - BioSpace
Price to sales forward of Passage Bio, Inc. – NASDAQ:PASG - TradingView
Price to book forward of Passage Bio, Inc. – NASDAQ:PASG - TradingView
Price to earnings forward of Passage Bio, Inc. – NASDAQ:PASG - TradingView
Passage Bio, Inc. Actuals & Estimates (BOATS:PASG) - TradingView
Baselake Partners (PASG) reports 235,058 shares, 7.3% ownership - Stock Titan
Remix Therapeutics secures $100M and a reverse merger - The Business Journals
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
Remix to go public in reverse merger with once high-flying Passage Bio - BioPharma Dive
PASG Forecast — Price Target — Prediction for 2027 - TradingView
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
Remix to enter Nasdaq through Passage Bio reverse merger - The Pharma Letter
Passage Bio and Remix Therapeutics Announce Merger to Advance RNA-Targeted Cancer Therapies with $100M Financing – Minichart - Minichart
SPRY, PASG, BOXL: Why These Stocks Plunged Double Digits In After-Hours Trading Today - TradingView
SGMOQ Stock Price and Chart — OTC:SGMOQ - TradingView
PASG Stock Slumps 16% After-Hours — What’s Driving The Selloff? - Asianet Newsable
Stocks to Watch: Micron, ARS Pharmaceuticals, MillerKnoll, Passage Bio - Moomoo
Passage Bio Shares Slide on Merger With Remix Therapeutics - Moomoo
Passage Bio And Remix Therapeutics Announce Merger Agreement - TradingView
Passage Bio (PASG) Slides 3.9% as Momentum Falters Near Key SupportWave Truncation - dars.gov.et
Spurned by the FDA, Passage Bio finds an exit through Remix - Fierce Biotech
Passage Bio (PASG) to merge with Remix; Remix private placement tops $100M - Stock Titan
Passage Bio to merge with Remix Therapeutics in all-stock deal - Investing.com
9 Health Care Stocks Moving In Wednesday's After-Market Session - Benzinga
Passage Bio to Merge With Remix Therapeutics; Remix Valued at $226M, $100M Financing - TradingView
Passage Bio (PASG) to combine with Remix; Remix valued at $226M, $100M raise - Stock Titan
Passage Bio | 425: Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactionsmoomoo - Moomoo
Remix Therapeutics to reverse-merge with Passage Bio (PASG) and raise $100M - Stock Titan
Passage Bio and Remix Therapeutics Announce Merger Agreement - GlobeNewswire
PASG Stock Slumps 16% After-HoursWhat's Driving The Selloff? - Menafn
Remix Therapeutics, Inc. entered into a definitive merger agreement to acquire Passage Bio, Inc. in a reverse merger transaction for approximately $230 million. - marketscreener.com
Passage Bio Inc (PASG) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Passage Bio Inc (PASG) Valuation: PE, PB & Fair Value Analysis - TradingKey
Passage Bio Inc (PASG) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Passage Bio Inc (PASG) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Passage Bio Inc (PASG) Institutional Confidence - TradingKey
Passage Bio Inc (PASG) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Passage Bio Inc (PASG) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Passage Bio Inc (PASG) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Passage Bio Inc (PASG) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Sea Limited’s Shopee Order Growth Reinforces E-Commerce MomentumEarnings Momentum Score - newsline.com
PRS Q1 2026 Earnings: Solid EPS Beat Driven by Core OperationsEarnings Deceleration Risk - newsline.com
Passage Bio Inc. (PASG) Surges Over 9% as Biotech Stock Tests Key ResistanceEarnings Quality Factor - newsline.com
Gartner (IT) Q1 2026 Earnings: EPS Surprises to the Upside Despite Modest Stock PullbackRevenue Recognition Risk - newsline.com
Fierce Biotech Layoff Tracker 2026: Genentech trims R&D; Neumora cuts 35% - Fierce Biotech
Guggenheim Downgrades Passage Bio(PASG.US) to Hold Rating - Moomoo
Passage Bio (PASG) Downgraded to Neutral as Strategic Review Ini - GuruFocus
Passage Bio (PASG) Slides 6.33% as Stock Approaches Key Support at $5.34SuperTrend - newsline.com
Thryv Holdings Faces Continued Pressure as Shares Slide to $3.72Dollar Neutral Pair - newsline.com
Gene and Cell Therapies Targeting CNS Disorders Market Expected to Experience Accelerated Growth and Market Evolution by 2036 – DelveInsight | Brainstorm Cell Therapeutics, MeiraGTx, Voyager Thera - Barchart.com
Passage Bio Inc. (PASG) Q1 2026 Earnings: Narrower-than-Expected Loss Drives Positive SentimentGAAP Earnings Report - newsline.com
PASG Q1 2026 Earnings: Narrower-Than-Expected Loss Lifts SentimentAnalyst Consensus Shift - newsline.com
Passage Bio Inc. (PASG) Edges Higher as Buyers Defend Key Support LevelCumulative Volume - The Legal Advocate
Passage Bio Inc. (PASG) Shows Modest Gains Amid Consolidation Near Key LevelsHigh Low Breadth - newsline.com
Unusual Machines (UMAC) Surges 57% as Momentum Builds Above Key SupportInstitutional Sentiment - The Legal Advocate
1.26%
3.59%
大文字化:
|
ボリューム (24 時間):